https://doi.org/10.1158/1078-0432.ccr-20-2488
Y
Yanxia Shi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
128
Papers
2.7K
Citations
24
h-index
41
i10-index
Yanxia Shi is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 24, co-authored 109 publications.
ORCID: 0000-0002-5414-8049Papers by this author
worksOpen-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
2020 · Clinical Cancer Research · 271 citations
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2023 · The Lancet Oncology · 84 citations
https://doi.org/10.1016/s1470-2045(23)00172-9
An assessment of prognostic immunity markers in breast cancer
2018 · npj Breast Cancer · 45 citations
https://doi.org/10.1038/s41523-018-0088-0
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
2019 · Cancer Letters · 45 citations
https://doi.org/10.1016/j.canlet.2019.01.005
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
2023 · Cancer Immunology Immunotherapy · 40 citations
https://doi.org/10.1007/s00262-023-03419-1
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance
2024 · The Oncologist · 32 citations
https://doi.org/10.1093/oncolo/oyae055
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat